Summary
BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study
BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
Becton, Dickinson and Company Q3 Earnings Call Highlights
Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.
BCAL Diagnostics Limited (BDX) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BCAL Diagnostics Limited ever had a stock split?
BCAL Diagnostics Limited Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Thomas E. Polen Jr. CEO | CXA Exchange | US0758871091 ISIN |
| US Country | 72,000 Employees | 9 Sep 2026 Last Dividend | 10 Feb 2026 Last Split | - IPO Date |
Overview
Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.
Products and Services
- BD Medical:
This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.
- BD Life Sciences:
In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.
- BD Interventional:
BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.
